This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Mitsubishi Tanabe Pharma Corporation

Drug Names(s): TA-6666

Description: TA-6666 is a dipeptidyl peptidase IV (DPP-IV) inhibitor. Through DPP IV enzyme inhibition, TA-6666maintains a level of endogeneous GLP-1 and leads to theacceleration of the secretion of insulin accompanying the rise inblood glucose level after meal intake, but it does not influenceinsulin secretion under fasting conditions.

Deal Structure: TA-6666 was developed by Tanabe.

In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.

TA-6666 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug